Vermont Legal Aid Inc
Rating: 5 stars 1 1 review 334
Po Box 1367 Burlington VT 05402 USA
To provide free legal services to vermonters who are low-income, elderly and those with disabilities.
Poverty law project represents low-income vermonters with civil legal problems in the areas of housing, family law, consumer law, employment, and problems with government benefits programs. This program serves clients who are below 200% of the federal poverty level.
health care advocate project operates a hotline providing advocacy on problems involving health care and health insurance. Case types include access to health care, billing, eligibility and insurance plan coverage issues.
elder law project represents people over 60 years of age in general and civil legal matters including housing, medicare and guardianship.
(1) disability law project represents vermonters with physical and developmental disabilities where their legal problems arise from their disability. Cases include guardianship, special education, discrimination in employment and housing, access to health care and social security disability-related benefits problems. Total expenses = 770,342. (2) mental health law project represents clients facing involuntary commitment and/ or involuntary medication proceedings. Total expenses = 635,837 including grants of 48,000. (3) long-term care ombudsman project represents individuals who receive long-term care services in nursing homes, residential care homes, assisted living residences, or in their own homes through the choices for care program. Issues addressed include quality of care, quality of life, and residents' rights. Total expenses = 563,801. (4) housing discrimination law project is established to conduct a full service, coordinated and comprehensive fair housing program under the private enforcement initiative of the u. S. Department of housing and urban development. Total expenses = 286,755. (5) vermont law help is a pilot project started to act as a screening and intake unit for the organization with a legal advice hotline that connects clients directly to attorneys. Total expenses = 191,137
Filter Reviews by Role
Promote This Nonprofit
GreatNonprofits badges allow you to raise awareness of your favorite nonprofits on your own web sites!
Reviews for Vermont Legal Aid Inc
THE REMARKABLE POTENTIAL HUMAN AND ECONOMIC VALUE OF ANTIDEPRESSANTS IN PREVENTING, ARRESTING, AND ALLEVIATING ALZHEIMER’S DISEASE: A MINIREVIEW
Julian Lieb, M.D
Twenty years ago, researchers knew that depression often accompanies and predisposes to the Alzheimer’s disease, the obvious inference: why not use antidepressants to prevent and treat Alzheimer’s? However, medical science is often peripheral to those exploiting the misfortunes of others. Today’s figure is $100,000,000 for preventing Alzheimer’s, with research based on the genome bubble.
Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A, Hayreh D, D'Angelo G, Benzinger T, Yoon H, Kim J, Morris JC, Mintun MA, Sheline YI. Proc Natl Acad Sci U S A. 2011 Sep 6; 108(36):14968-73. Epub 2011 Aug 22. PMID: 21873225 [PubMed - indexed for MEDLINE]
Improving depression and enhancing resilience in family dementia caregivers: a pilot randomized placebo-controlled trial of escitalopram. Lavretsky H, Siddarth P, Irwin MR. Am J Geriatr Psychiatry. 2010 Feb; 18(2):154-62.PMID: 20104071 [PubMed - indexed for MEDLINE
Anti-inflammatory effects of antidepressants: possibilities for preventives against Alzheimer's disease. Hashioka S, McGeer PL, Monji A, Kanba S. Cent Nerv Syst Agents Med Chem. 2009 Mar; 9(1):12-9. Review.PMID: 20021334 [PubMed - indexed for MEDLINE]
Imipramine, in part through tumor necrosis factor alpha inhibition, prevents cognitive decline and beta-amyloid accumulation in a mouse model of Alzheimer's disease.
Chavant F, Deguil J, Pain S, Ingrand I, Milin S, Fauconneau B, Pérault-Pochat MC, Lafay-Chebassier C. J Pharmacol Exp Ther. 2010 Feb; 332(2):505-14. Epub 2009 Nov 4.
Involuntary emotional expression disorder in Alzheimer's disease - psychopharmacotherapy aspects. Mimica N, Drmić S, Presecki P. Psychiatr Danub. 2009 Sep; 21(3):425-8.
Untangling the roles of antidepressants and mood stabilizers in the treatment of Alzheimer's disease. Introduction. Reiman EM. J Clin Psychiatry. 2009 Jun;70(6):913-4. No abstract available.
Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease. Siddique H, Hynan LS, Weiner MF. J Clin Psychiatry. 2009 Jun; 70(6):915-8. Epub 2009 May 5.
Antidepressants and dementia. Kessing LV, Søndergård L, Forman JL, Andersen PK.
J Affect Disord. 2009 Sep; 117(1-2):24-9. Epub 2009 Jan 12.Int Rev Psychiatry. 2008 Aug; 20(4):382-8.
Effect of citalopram in treating hypersexuality in an Alzheimer's disease case.
Tosto G, Talarico G, Lenzi GL, Bruno G. Neurol Sci. 2008 Sep; 29(4):269-70. Epub 2008 Sep 20
Is antidepressant treatment associated with reduced cognitive decline in Alzheimer's disease? Mossello E, Boncinelli M, Caleri V, Cavallini MC, Palermo E, Di Bari M, Tilli S, Sarcone E, Simoni D, Biagini CA, Masotti G, Marchionni N. Department of Critical Care Medicine and Surgery, Unit of Gerontology and Geriatric Medicine, University of Florence and Azienda Ospedaliero-Universitaria Careggi, Florence, Italy. email@example.com J Biol Chem. 2007 Nov 9; 282(45):32676-88. Epub 2007 Sep 2.
Involvement of prostaglandin E2 in production of amyloid-beta peptides both in vitro and in vivo. Hoshino T, Nakaya T, Homan T, Tanaka K, Sugimoto Y, Araki W, Narita M, Narumiya S, Suzuki T, Mizushima T.Graduate School of Medical and Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Kumamoto 862-0973, Japan. J Biol Chem. 2007 Nov 9; 282(45):32676-88. Epub 2007 Sep 2.
Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. Henry G, Williamson D, Tampi RR.Am J Alzheimer’s Dis Other Demen. 2011 May; 26(3):169-83. Epub 2011 Mar 23. Review PMID: 21429956 [PubMed - indexed for MEDLINE]
PLoS One. 2011; 6(6):e21660. Epub 2011 Jun 27.
Amitriptyline-mediated cognitive enhancement in aged 3×Tg Alzheimer's disease mice is associated with neurogenesis and neurotrophic activity.Chadwick W, Mitchell N, Caroll J, Zhou Y, Park SS, Wang L, Becker KG, Zhang Y, Lehrmann E, Wood WH 3rd, Martin B, Maudsley S. Receptor Pharmacology Unit, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, United States of America.
BIOCHEMICAL AND PHARMACOLOGICAL INTERPRETATIONS
As depression predisposes to Alzheimer’s disease, it is not surprising that antidepressants are capable of preventing, alleviating and arresting the disorder. Excessive synthesis of prostaglandin E2 generates amyloid, and such non-steroidal anti-inflammatory drugs as aspirin and ibuprofen, as well as antidepressants, inhibit prostaglandin E2. Two epidemiological studies have shown that ibuprofen (Motrin), that inhibit prostaglandin E2, can delay the onset of Parkinson’s disease, a neurodegenerative disorder closely related to Alzheimer’s.
Antidepressants offer great advantages, and few disadvantages, in addressing Alzheimer’s, recently referred to as “the coming tsunami,” but you would not think so, given the lack of enthusiasm of Alzheimer’s organizations and health policy makers, when notified of this innovation. One suspects that conflicts of interest, and the low cost of generic antidepressants, are the root causes of the neglect.
The right to the highest attainable standard of health is codified in numerous legally binding international and regional human rights treaties. The right, or other health-related rights, is also enshrined in over 100 constitutions worldwide.
Article19 of the universal declaration of human rights.
• Everyone has the right to freedom of opinion and expression; this right includes freedom to hold opinions without interference and to seek, receive and impart information and ideas through any media and regardless of frontiers.
Many additional references in Pubmed.
For educational purposes only.
Julian Lieb, M.D
Retired, Yale medical school professor
Available in 1990, will not be imitated, permanent damage to society.
How does this organization compare with others in the same sector?
How much of an impact do you think this organization has?
Will you recommend this organization to others?
When was your last experience with this nonprofit?